GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Aim Pharm Inc (SZSE:002826) » Definitions » EV-to-Revenue

Tibet Aim Pharm (SZSE:002826) EV-to-Revenue : 2.00 (As of May. 27, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Tibet Aim Pharm EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Tibet Aim Pharm's enterprise value is ¥1,310.9 Mil. Tibet Aim Pharm's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥656.0 Mil. Therefore, Tibet Aim Pharm's EV-to-Revenue for today is 2.00.

The historical rank and industry rank for Tibet Aim Pharm's EV-to-Revenue or its related term are showing as below:

SZSE:002826' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.65   Med: 3.32   Max: 10.96
Current: 2

During the past 10 years, the highest EV-to-Revenue of Tibet Aim Pharm was 10.96. The lowest was 1.65. And the median was 3.32.

SZSE:002826's EV-to-Revenue is ranked better than
55.23% of 1023 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs SZSE:002826: 2.00

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-27), Tibet Aim Pharm's stock price is ¥9.07. Tibet Aim Pharm's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥3.60. Therefore, Tibet Aim Pharm's PS Ratio for today is 2.52.


Tibet Aim Pharm EV-to-Revenue Historical Data

The historical data trend for Tibet Aim Pharm's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tibet Aim Pharm EV-to-Revenue Chart

Tibet Aim Pharm Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.56 3.31 2.83 2.64 1.96

Tibet Aim Pharm Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.08 2.12 2.38 2.84 1.91

Competitive Comparison of Tibet Aim Pharm's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Aim Pharm's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tibet Aim Pharm's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Aim Pharm's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Tibet Aim Pharm's EV-to-Revenue falls into.



Tibet Aim Pharm EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Tibet Aim Pharm's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1310.899/656.034
=2.00

Tibet Aim Pharm's current Enterprise Value is ¥1,310.9 Mil.
Tibet Aim Pharm's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥656.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tibet Aim Pharm  (SZSE:002826) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Tibet Aim Pharm's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=9.07/3.601
=2.52

Tibet Aim Pharm's share price for today is ¥9.07.
Tibet Aim Pharm's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3.60.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tibet Aim Pharm EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tibet Aim Pharm's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Tibet Aim Pharm (SZSE:002826) Business Description

Traded in Other Exchanges
N/A
Address
No. 6, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Aim Pharm Inc is the pharmaceutical company based in China. It is mainly engaged in the research and development, production and sales of chemical drugs and proprietary Chinese medicines for common chronic disease such as diabetes and cardiovascular disease as well as medicines for gynecology and obstetrics. The company's products offering includes miglitol tablets, gualoupi injection, nalmefene hydrochloride injection, carbetocin injection; hongjin xiaojie tablets and aceclofenac enteric-coated tablets. The company also expanded its products in the treatment of antibiotic, antiallergic and digestive system.
Executives
Peng Hui Director
Pang Guo Qiang Directors, executives
Li Qian Jin Securities Affairs Representative
Liu Hang Supervisors

Tibet Aim Pharm (SZSE:002826) Headlines

No Headlines